A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Information source: San Bernardino Urological Associates Medical Group Inc
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cancer of Prostate
Intervention: leuprolide acetate (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: San Bernardino Urological Associates Medical Group Inc Official(s) and/or principal investigator(s):
Franklin M Chu, MD, Principal Investigator, Affiliation: San Bernfardino Urological Associates
Summary
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone
levels are measured at set intervals to determine if Eligard is equal or better then Lupron
or Zoladex in advanced Prostate Cancer patients.
Clinical Details
Official title: A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Study design: Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria: Patient with Advanced Ca, on stable dose of Lupron or Zoladex
-
Exclusion Criteria:
- Previous exposure to Eligard.
Locations and Contacts
San bernardino Urological Associates Medical Group, San Bernardino, California 92404, United States
Additional Information
Starting date: April 2003
Ending date: June 2005
Last updated: October 19, 2005
|
